3 recruiting, 1 active not recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Active not recruiting 1 |
Follow Autoimmune Lymphoproliferative: new trials by email Literature Review of Autoimmune Lymphoproliferative trials Research Report on Autoimmune Lymphoproliferative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition Emapalumab, Fludarabine and Dexamethasone, Allogeneic hematopoietic stem cell transplant (allo-HCT) - Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative | Phase 2 | Recruiting | Joseph Oved | 39 | 2023-03-15 | 2026-06-02 |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Busulfan test dose, Fludarabine, Busulfan - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2020-09-22 | 2026-10-19 |
| Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2018-09-04 | 2026-03-17 |
| Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies Immunosuppression Only Conditioning -Closed with amendment L, Reduced Intensity Conditioning, Myeloablative Conditioning-Closed with amendment L - Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency | Phase 2 | Recruiting | National Cancer Institute (NCI) | 354 | 2015-11-19 | 2026-10-26 |
Immune System Diseases (4) · Autoimmune Diseases (3) · Common Variable Immunodeficiency (3) · Lymphoproliferative Disorders (3) · Opportunistic Infections (3) · T cell immunodeficiency primary (3)
Hemic and Lymphatic Diseases (3) · Immunologic Deficiency Syndromes (3) · Immunoproliferative Disorders (3) · Infections (3) · Lymphatic Diseases (3)
Busulfan (2) · Cyclophosphamide (2) · Mycophenolic Acid (2) · Tacrolimus (2) · fludarabine (2) · Absorptiometry, Photon (1) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Biopsy (1) · Dexamethasone (1) · Electrocardiography (1) · Emapalumab (1) · Mesna (1) · Pentostatin (1) · Prednisone (1)
National Cancer Institute (NCI) (3) · Joseph Oved (1)
United States (4)
Dimana Dimitrova, M.D. (2) · Joseph Oved, MD (1) · Sung-Yun Pai, M.D. (1)